AXIM Biotech chooses the iPeak® for the Dry Eye Disease Diagnostics

Founded in 2014 in California, AXIM® Biotechnologies, Inc. is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

AXIM has signed an agreement with IUL for its iPeak® DED readers which have been deployed for diagnostic testing with a focus on lactoferrin levels. This state-of-the-art portable reader is a colorimetric lateral flow reader designed to hold different cassette sizes and can read cassettes of up to five strips and seven lines per strip at a time.



The iPeak® picked over 6 Lateral Flow Readers


AXIM evaluated the iPeak® readers in the lab against six other comparable products before deciding on IUL’s state-of-the-art products. The new readers have been calibrated with the new test strips and will soon be distributed to the Company’s Medical Advisory Board (MAB) of renowned DED experts for non-clinical field testing on their patients, which includes studying the accuracy and ease of use.

The Company’s diagnostic testing process for DED, and specifically for lactoferrin levels as a primary indicator, includes the use of reagent strip samples. These strips have the patients’ tear sample obtained and applied and then an ophthalmologist or optometrist runs the strips through an iPeak reader to determine lactoferrin levels and incidence and severity of DED.

After extensive due diligence, we fully expect our supply agreement with IUL will enable us to transform the DED diagnostic testing market with the highest quality readers available and an approach that is light years ahead of industry competitors

Said by John Huemoeller, CEO of AXIM Biotech.“We have the only FDA-cleared quantitative test for Dry Eye Disease and believe that it has tremendous accuracy and convenient ease of use for ophthalmologists as well as frontline optometrists.”




The sensitivity of iPeak® was key


The iPeak® is equipped with “Flash Eye” technology based on the principles of machine vision illumination. Its camera captures the image of the test illuminated from LED lights situated in the most studied geometry to achieve a precise and uniform illumination and enhance the colors of any lateral flow test. The iPeak® technology also allows for more sensitivity, which is the main success of its application.


Interested In Working With Us?